AKT-IN-27 (4a) is a potential anticancer drug that functions by selectively targeting Akt-driven signaling pathways. It induces apoptosis by activating caspase-3, causing G2/M phase cell cycle arrest, and disrupting mitochondrial membrane potential. AKT-IN-27 (4a) is applicable in research on triple-negative breast cancer (TNBC).
Molecular Weight:
377.41
Formula:
C21H15NO4S
Target:
Apoptosis|||Akt
T207441
* VAT and and shipping costs not included. Errors and price changes excepted
